Figure 1.
Kinetics of MRD during venetoclax therapy. (A) Serial peripheral blood MRD status during venetoclax therapy. (B) Cumulative incidence of attainment of uMRD in the peripheral blood. Dotted line shows 24 months on therapy, at which time 90% of ultimate peripheral blood uMRD was achieved, excluding 2 nonrepresentative late events (significant delay to MRD assessment).